The GeneType team is excited to announce that the Colorectal Cancer Risk Assessment Test isnow available for purchasethrough a 3rd party telehealth provider!
Due to the pandemic, the rates of routine colorectal cancer screenings have gone down. In honor of Colorectal Cancer Awareness month, we are encouraging all of our subscribers to get back on track and receive their recommended screenings.
Here are a few keyrisk factorsfor colorectal cancer:
- Age
- Family history
- Genomics
- Ethnicity/Race
- Your health conditions
What makes GeneType for Colorectal Cancer so effective is that it considers your age, family history,andpersonal genetic makeup in one comprehensive risk assessment.
The test will tell you if you have an average or increased risk for colorectal cancer. Once you receive your results, you and your healthcare provider can use this information to develop a personalized screening and risk reduction plan.
Take charge of your health today and know your risk with GeneType for Colorectal Cancer!
- Forums
- ASX - By Stock
- News: GTG Genetic Technologies Signs Multi-Year US Distribution Agreement For COVID Risk Test
"s on in my mailbox :The GeneType team is excited to announce...
-
-
- There are more pages in this discussion • 30 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add GTG (ASX) to my watchlist
(20min delay)
|
|||||
Last
3.9¢ |
Change
0.000(0.00%) |
Mkt cap ! $5.671M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
GTG (ASX) Chart |
Day chart unavailable
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Michael Thurn, CEO & MD
Michael Thurn
CEO & MD
SPONSORED BY The Market Online